PDL BioPharma (PDLI) says it expects Q3 revenue of $83M (-3% Y/Y), guidance below analyst...

|About: PDL BioPharma, Inc. (PDLI)|By:, SA News Editor

PDL BioPharma (PDLI) says it expects Q3 revenue of $83M (-3% Y/Y), guidance below analyst estimates of $87.7M. The firm expects reduced royalty revenue from Avastin to only be partially offset by an increase in royalties from Herceptin, Lucenits and Tysabi. Shares -1.2% premarket.